CoChat

A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer

Open access
Dijkgraaf, Eveline M., Santegoets, Saskia J.A.M., Reyners, An K.L., Goedemans, Renske, Nijman, Hans W., van Poelgeest, Mariëtte I.E., van Erkel, Arien R., Smit, Vincent T.H.B.M., Daemen, Toos A.H.H., van der Hoeven, Jacobus J.M., Melief, Cornelis J.M., Welters, Marij J.P., Kroep, Judith R., van der Burg, Sjoerd H. · 2015 · Oncotarget
Cited by 83

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

// Eveline M. Dijkgraaf 1 , Saskia J.A.M. Santegoets 1 , An K.L. Reyners 2 , Renske Goedemans 1 , Hans W. Nijman 3 , Mariëtte I.E. van Poelgeest 4 , Arien R. van Erkel 5 , Vincent T.H.B.M. Smit 6 , Toos A.H.H. Daemen 7 , Jacobus J.M. van der Hoeven 1 , Cornelis J.M. Melief 8 , Marij J.P. Welters 1 , Judith R. Kroep 1, * , Sjoerd H. van der Burg 1, * 1 Department of Medical Oncology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands 2 Department of Clinical Oncology, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands 3 Department of Gynecologic Oncology, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands 4 Department of Gynecology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands 5 Department of Radiology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands 6 Department of Pathology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands 7 Department of Medical Microbiology, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands 8 Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands * These authors have contributed equally to this work Correspondence to: Sjoerd H. van der Burg, e-mail: shvdburg@lumc.nl Judith R. Kroep, e-mail: j.r.kroep@lumc.nl Keywords: ovarian cancer, p53, immunotherapy, chemoresistance, tumor immunity Received: May 27, 2015 Accepted: August 03, 2015 Published: August 14, 2015 ABSTRACT Purpose : Preclinical tumor models show that chemotherapy has immune modulatory properties which can be exploited in the context of immunotherapy. The purpose of this study was to determine the feasibility and immunogenicity of combinations of such an immunomodulatory chemotherapeutic agent with immunotherapy, p53 synthetic long peptide (SLP) vaccine and Pegintron (IFN-α) in patients with platinum-resistant p53-positive epithelial ovarian cancer (EOC). Experimental design : This is a phase 1/2 trial in which patients sequential 6 cycles of gemcitabine (1000 mg/kg 2 iv; n = 3), gemcitabine with Pegintron before and after the first gemcitabine cycle (Pegintron 1 μg/kg sc; n = 6), and gemcitabine and Pegintron combined with p53 SLP vaccine (0.3 mg/peptide, 9 peptides; n = 6). At baseline, 22 days after the 2 nd and 6 th cycle, blood was collected for immunomonitoring. Toxicity, CA-125, and radiologic response were evaluated after 3 and 6 cycles of chemotherapy. Results : None of the patients enrolled experienced dose-limiting toxicity. Predominant grade 3/4 toxicities were nausea/vomiting and dyspnea. Grade 1/2 toxicities consisted of fatigue (78%) and Pegintron-related flu-like symptoms (72%). Gemcitabine reduced myeloid-derived suppressor cells ( p = 0.0005) and increased immune-supportive M1 macrophages ( p = 0.04). Combination of gemcitabine and Pegintron stimulated higher frequencies of circulating proliferating CD4+ and CD8+ T-cells but not regulatory T-cells. All vaccinated patients showed strong vaccine-induced p53-specific T-cell responses. Conclusion : Combination of gemcitabine, the immune modulator Pegintron and therapeutic peptide vaccination is a viable approach in the development of combined chemo-immunotherapeutic regimens to treat cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.4772

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 83

Metadata

Authors
Dijkgraaf, E. M., Santegoets, S. J. A. M., Reyners, A. K. L., Goedemans, R., Nijman, H. W., van Poelgeest, M. I. E., van Erkel, A. R., Smit, V. T. H. B. M., Daemen, T. A. H. H., van der Hoeven, J. J. M., Melief, C. J. M., Welters, M. J. P., Kroep, J. R., & van der Burg, S. H.
Venue
Oncotarget
Published
2015-08-14
Volume
6
Issue
31
Pages
32228-32243
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1960571207
Cited by
83
References
8
FWCI
8.85
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.